

03/31/2005 09730663.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks
(ROSPATENT) added to list of core patent offices covered
NEWS 4 FEB 28 PATDPAFULL - New display fields provide for legal status
data from INPADOC
NEWS 5 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 6 FEB 28 MEDLINE/LMEDLINE reloaded
NEWS 7 MAR 02 GBFULL: New full-text patent database on STN
NEWS 8 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 9 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 10 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 11 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 12 MAR 22 PATDPASPC - New patent database available
NEWS 13 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:33:34 ON 31 MAR 2005

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 16:33:42 ON 31 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Mar 2005 VOL 142 ISS 14
FILE LAST UPDATED: 30 Mar 2005 (20050330/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s celecoxib
L1      1505 CELECOXIB

=> s l1 and amorphous
      240510 AMORPHOUS
      5 AMORPHOUSES
      240514 AMORPHOUS
      (AMORPHOUS OR AMORPHOUSES)
L2      13 L1 AND AMORPHOUS

=> s l2 and calorimetry
      54049 CALORIMETRY
      21 CALORIMETRIES
      54060 CALORIMETRY
      (CALORIMETRY OR CALORIMETRIES)
L3      4 L2 AND CALORIMETRY

=> s l2 and glass transition
      664609 GLASS
      127989 GLASSES
      692699 GLASS
      (GLASS OR GLASSES)
      877497 TRANSITION
      244147 TRANSITIONS
      984065 TRANSITION
      (TRANSITION OR TRANSITIONS)
      72521 GLASS TRANSITION
      (GLASS(W) TRANSITION)
L4      4 L2 AND GLASS TRANSITION

=> s l2 and py<=1999
      19743562 PY<=1999
L5      0 L2 AND PY<=1999

=> d l4 ibib abs hitstr tot
```

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:250983 CAPLUS

TITLE: Molecular interactions in **celecoxib**
-PVP-meglumine **amorphous** system

AUTHOR(S): Gupta, Piyush; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology
(Formulations), National Institute of Pharmaceutical
Education and Research (NIPER), S.A.S. Nagar, 160 062,
IndiaSOURCE: Journal of Pharmacy and Pharmacology (2005), 57(3),
303-310

CODEN: JPPMAB; ISSN: 0022-3573

PUBLISHER: Pharmaceutical Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Stabilization of the **amorphous** form of a drug is conferred by additives that interact with it at the mol. level. Ternary systems of **celecoxib**, poly(vinyl pyrrolidone) (PVP) and meglumine were studied for mol. interactions responsible for enhanced drug stability and solubility in **amorphous** form. Meglumine was found to lower the **glass transition** temperature (T_g) of the drug due to its plasticization effect. However, the presence of PVP masked its destabilizing effect and provided net anti-plasticization to the **celecoxib**-PVP-meglumine (7:2:1 weight/weight) ternary **amorphous** system. Pos. deviation of the exptl. determined T_g mix value for this composition, from those predicted by the Gordon-Taylor/Kelley-Bueche equation, inferred mol. interaction between the three species, which was also supported by band shifts from their Fourier-transform infra-red (FTIR) spectra. Further, shift of differential scanning calorimetry (DSC) melting endotherms of **celecoxib** in its **amorphous** systems from those observed for crystalline **celecoxib** confirmed the complexation between these components, which was also substantiated by mol. modeling studies that showed H-bonding of -S=O, 2-N of the pyrazole ring and -C-F groups of **celecoxib** with -O-H group of meglumine. These mol. interactions of **amorphous celecoxib** with meglumine were found to be the potential cause for enhanced stability and solubility of the **celecoxib**-PVP-meglumine ternary system.

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:861964 CAPLUS

DOCUMENT NUMBER: 142:183060

TITLE: Stability and Solubility of **Celecoxib**-PVP**Amorphous** Dispersions: A Molecular Perspective

AUTHOR(S): Gupta, Piyush; Kakumanu, Vasu Kumar; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology
(Formulations), National Institute of Pharmaceutical
Education and Research, Punjab, 160 062, India

SOURCE: Pharmaceutical Research (2004), 21(10), 1762-1769

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Springer Science+Business Media, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of the current study is to evaluate the solubility advantage offered by **celecoxib** (CEL) **amorphous** systems and to characterize and correlate the phys. and thermodyn. properties of CEL and its **amorphous** mol. dispersions containing poly(vinylpyrrolidone) (PVP). The measurement of crystalline content, **glass**

transition temps., and enthalpy relaxation was performed using differential scanning calorimetry. Solubility and dissolns. studies were conducted at 37°C to elucidate release mechanisms. Further, the **amorphous** systems were characterized by polarized light microscopy and x-ray powder diffraction studies. The PVP content has a prominent effect on the stability and solubility profiles of **amorphous** systems. A dispersion of 20% weight/weight PVP with CEL resulted in a maxima in terms of solubility enhancement and lowering of relaxation enthalpy. The release of drug from **amorphous** mol. dispersions was found to be drug-dependent and independent of the carrier. The solubility enhancement and enthalpy relaxation studies with respect to PVP concentration helped in a better

prediction of role of carrier and optimization of concentration in the use of solid dispersions or **amorphous** systems. The drug release mechanism is drug-controlled rather than carrier-controlled.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:782310 CAPLUS

DOCUMENT NUMBER: 141:319758

TITLE: Physical Stability and Solubility Advantage from

Amorphous Celecoxib: The Role of

Thermodynamic Quantities and Molecular Mobility

AUTHOR(S): Gupta, Piyush; Chawla, Garima; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology
(Formulations), National Institute of Pharmaceutical
Education and Research, Punjab, 160062, India

SOURCE: Molecular Pharmaceutics (2004), 1(6), 406-413

CODEN: MPOHBP; ISSN: 1543-8384

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Glassy pharmaceuticals, characterized by excess thermodyn. properties, are theor. more soluble than their crystalline counterparts. The practical solubility

advantage of the **amorphous** form of **celecoxib** (CEL) is lost due to its proclivity to lose energy and undergo solvent-mediated devitrification. Theor. assessment of solubility advantage using differences in isobaric heat capacities (C_p) revealed a 7-21-fold enhancement in the solubility of the **amorphous** form over that of the crystalline state of CEL. The present study attempts to unveil these differences between exptl. and theor. solubility using thermodyn. parameters such as free energy, enthalpy, and entropy. **Amorphous** CEL exhibited 1.3-1.5 times enhancement in C_p over that for the crystalline form. The zero and critical

mol.

mobility regions, represented by Kauzmann temperature (T_K) and **glass transition** temperature (T_g), were found to lie near 246 and 323 K, resp., for **amorphous** CEL. The fictive temperature (T_f), an indicator of the configurational entropy of glass, was determined for glassy CEL, signifying the retention of considerable mol. mobility in the glassy phase that may favor nucleation even below T_g . Further, the estimation of various thermodyn. quantities and strength/fragility parameters ($D = 11.5$ and $m = 67.0$) postulated the classification of glassy CEL into moderately fragile liquid, as per Angell's classification. A comprehensive understanding of such thermodyn. facets of **amorphous** form would help in rationalizing the approaches toward development of stable glassy pharmaceuticals with adequate solubility advantage.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:940035 CAPLUS

DOCUMENT NUMBER: 139:169110

TITLE: Enthalpy Relaxation Studies of **Celecoxib**
Amorphous Mixtures

AUTHOR(S): Kakumanu, Vasu Kumar; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology, National
Institute of Pharmaceutical Education and Research,
Punjab, 160 062, India

SOURCE: Pharmaceutical Research (2002), 19(12), 1873-1878

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Kluwer Academic/Plenum Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of this study was to compare the structural relaxation and mol. mobility of **amorphous celecoxib** (CEL) with that of CEL **amorphous** mixts. consisting of various excipients and to study the effect of different excipients on the relaxation of high-energy **amorphous** systems. The measurement of **glass transition** temps. (Tg) and enthalpy relaxation were performed using differential scanning calorimetry. The interactions between drug and excipients and the absence of crystalline forms were further confirmed by conducting Fourier transform IR spectroscopic and x-ray powder diffraction studies on same samples. All samples exhibited a single Tg value. Polymers had a prominent effect on the lowering of the relaxation rate in **amorphous** CEL. The lowering of the rate of relaxation was directly dependent on the concentration and type of polymer used. The total enthalpy required for relaxation was same, although additives affected the rate of relaxation. In absence of any specific interactions during Fourier transform IR studies, it was concluded that the anti-plasticizing activity of polymers is responsible for the stabilization of CEL **amorphous** systems. Glassy **amorphous** dispersions of CEL exhibited a complex type of relaxation pattern, which failed to fit in Kohlrausch-Williams-Watts equation with respect to calcn. of relaxation time consts.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 13 ibib abs hitstr tot

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:250983 CAPLUS

TITLE: Molecular interactions in **celecoxib**
-PVP-meglumine **amorphous** system

AUTHOR(S): Gupta, Piyush; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology
(Formulations), National Institute of Pharmaceutical
Education and Research (NIPER), S.A.S. Nagar, 160 062,
IndiaSOURCE: Journal of Pharmacy and Pharmacology (2005), 57(3),
303-310

CODEN: JPPMAB; ISSN: 0022-3573

PUBLISHER: Pharmaceutical Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Stabilization of the **amorphous** form of a drug is conferred by

additives that interact with it at the mol. level. Ternary systems of **celecoxib**, poly(vinyl pyrrolidone) (PVP) and meglumine were studied for mol. interactions responsible for enhanced drug stability and solubility in **amorphous** form. Meglumine was found to lower the glass transition temperature (Tg) of the drug due to its plasticization effect. However, the presence of PVP masked its destabilizing effect and provided net anti-plasticization to the **celecoxib**-PVP-meglumine (7:2:1 weight/weight) ternary **amorphous** system. Pos. deviation of the exptl. determined Tg mix value for this composition, from those predicted by the Gordon-Taylor/Kelley-Bueche equation, inferred mol. interaction between the three species, which was also supported by band shifts from their Fourier-transform infra-red (FTIR) spectra. Further, shift of differential scanning **calorimetry** (DSC) melting endotherms of **celecoxib** in its **amorphous** systems from those observed for crystalline **celecoxib** confirmed the complexation between these components, which was also substantiated by mol. modeling studies that showed H-bonding of -S=O, 2-N of the pyrazole ring and -C-F groups of **celecoxib** with -O-H group of meglumine. These mol. interactions of **amorphous celecoxib** with meglumine were found to be the potential cause for enhanced stability and solubility of the **celecoxib**-PVP-meglumine ternary system.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:241234 CAPLUS

TITLE: Complexation of **celecoxib** with
 β -cyclodextrin: characterization of the
interaction in solution and in solid state

AUTHOR(S): Sinha, V. R.; Anitha, R.; Ghosh, S.; Nanda, A.;
Kumria, R.

CORPORATE SOURCE: University Institute of Pharmaceutical Sciences,
Panjab University, Chandigarh, 160014, India

SOURCE: Journal of Pharmaceutical Sciences (2005), 94(3),
676-687

CODEN: JPMSAE; ISSN: 0022-3549

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Inclusion complexation between **celecoxib**, a specific
cyclooxygenase II inhibitor, and beta-cyclodextrin (β -CD) was studied
in solution and solid state. Drug cyclodextrin complexes were prepared by
spray drying while phys. mixts. were obtained by simple blending.
Inclusion complexes were characterized by NMR spectroscopy (NMR),
differential scanning **calorimetry** (DSC), X-ray diffractometry
(XRD), SEM (SEM), IR spectroscopy (IR), and polarimetry. Phase solubility
anal. was carried out to determine the stability constant Solubility studies
revealed

the existence of a 1:1 complex between **celecoxib** and β -CD.

NMR studies suggested a strong interaction between **celecoxib** and
 β -CD prepared by spray drying. XRD and SEM anal. illustrated that
celecoxib existed as an **amorphous** complexed form in

spray-dried complexes. Dissoln. studies showed that the **celecoxib**
entrapped in spray-dried complexes dissolved much faster than the
uncomplexed drug and phys. mixts. The data obtained suggest that

celecoxib forms an inclusion complex with β -CD in solution and
solid state, which was confirmed by various anal. techniques. A shorter
t50% of dissoln. is found for the formulation prepared by spray drying when
compared on a weight basis in a USP II apparatus

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:861964 CAPLUS

DOCUMENT NUMBER: 142:183060

TITLE: Stability and Solubility of **Celecoxib**-PVP**Amorphous** Dispersions: A Molecular Perspective

AUTHOR(S): Gupta, Piyush; Kakumanu, Vasu Kumar; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology
(Formulations), National Institute of Pharmaceutical
Education and Research, Punjab, 160 062, India

SOURCE: Pharmaceutical Research (2004), 21(10), 1762-1769

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Springer Science+Business Media, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of the current study is to evaluate the solubility advantage offered by **celecoxib** (CEL) **amorphous** systems and to characterize and correlate the phys. and thermodyn. properties of CEL and its **amorphous** mol. dispersions containing poly(vinylpyrrolidone) (PVP). The measurement of crystalline content, glass transition temps., and enthalpy relaxation was performed using differential scanning calorimetry. Solubility and dissolns. studies were conducted at 37°C to elucidate release mechanisms. Further, the **amorphous** systems were characterized by polarized light microscopy and x-ray powder diffraction studies. The PVP content has a prominent effect on the stability and solubility profiles of **amorphous** systems. A dispersion of 20% weight/weight PVP with CEL resulted in a maxima in terms of solubility enhancement and lowering of relaxation enthalpy. The release of drug from **amorphous** mol. dispersions was found to be drug-dependent and independent of the carrier. The solubility enhancement and enthalpy relaxation studies with respect to PVP concentration helped in a better prediction of role of carrier and optimization of concentration in the use of solid dispersions or **amorphous** systems. The drug release mechanism is drug-controlled rather than carrier-controlled.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:940035 CAPLUS

DOCUMENT NUMBER: 139:169110

TITLE: Enthalpy Relaxation Studies of **Celecoxib****Amorphous** Mixtures

AUTHOR(S): Kakumanu, Vasu Kumar; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology, National
Institute of Pharmaceutical Education and Research,
Punjab, 160 062, India

SOURCE: Pharmaceutical Research (2002), 19(12), 1873-1878

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Kluwer Academic/Plenum Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of this study was to compare the structural relaxation and mol. mobility of **amorphous celecoxib** (CEL) with that of CEL **amorphous** mixts. consisting of various excipients and to study the effect of different excipients on the relaxation of high-energy **amorphous** systems. The measurement of glass transition temps. (Tg) and enthalpy relaxation were performed using differential scanning calorimetry. The interactions between drug and excipients and the

absence of crystalline forms were further confirmed by conducting Fourier transform IR spectroscopic and x-ray powder diffraction studies on same samples. All samples exhibited a single Tg value. Polymers had a prominent effect on the lowering of the relaxation rate in **amorphous** CEL. The lowering of the rate of relaxation was directly dependent on the concentration and type of polymer used. The total enthalpy required for relaxation was same, although additives affected the rate of relaxation. In absence of any specific interactions during Fourier transform IR studies, it was concluded that the anti-plasticizing activity of polymers is responsible for the stabilization of CEL **amorphous** systems. Glassy **amorphous** dispersions of CEL exhibited a complex type of relaxation pattern, which failed to fit in Kohlrausch-Williams-Watts equation with respect to calcn. of relaxation time consts.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2 ibib abs hitstr tot

L2 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:250983 CAPLUS

TITLE: Molecular interactions in **celecoxib**
-PVP-meglumine **amorphous** system

AUTHOR(S): Gupta, Piyush; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology
(Formulations), National Institute of Pharmaceutical
Education and Research (NIPER), S.A.S. Nagar, 160 062,
India

SOURCE: Journal of Pharmacy and Pharmacology (2005), 57(3),
303-310

CODEN: JPPMAB; ISSN: 0022-3573

PUBLISHER: Pharmaceutical Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Stabilization of the **amorphous** form of a drug is conferred by additives that interact with it at the mol. level. Ternary systems of **celecoxib**, poly(vinyl pyrrolidone) (PVP) and meglumine were studied for mol. interactions responsible for enhanced drug stability and solubility in **amorphous** form. Meglumine was found to lower the glass transition temperature (Tg) of the drug due to its plasticization effect. However, the presence of PVP masked its destabilizing effect and provided net anti-plasticization to the **celecoxib**-PVP-meglumine (7:2:1 weight/weight) ternary **amorphous** system. Pos. deviation of the exptl. determined Tg mix value for this composition, from those predicted by the Gordon-Taylor/Kelley-Bueche equation, inferred mol. interaction between the three species, which was also supported by band shifts from their Fourier-transform infra-red (FTIR) spectra. Further, shift of differential scanning calorimetry (DSC) melting endotherms of **celecoxib** in its **amorphous** systems from those observed for crystalline **celecoxib** confirmed the complexation between these components, which was also substantiated by mol. modeling studies that showed H-bonding of -S=O, 2-N of the pyrazole ring and -C-F groups of **celecoxib** with -O-H group of meglumine. These mol. interactions of **amorphous celecoxib** with meglumine were found to be the potential cause for enhanced stability and solubility of the **celecoxib**-PVP-meglumine ternary system.

L2 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:241234 CAPLUS
TITLE: Complexation of **celecoxib** with
 β -cyclodextrin: characterization of the
interaction in solution and in solid state
AUTHOR(S): Sinha, V. R.; Anitha, R.; Ghosh, S.; Nanda, A.;
Kumria, R.
CORPORATE SOURCE: University Institute of Pharmaceutical Sciences,
Panjab University, Chandigarh, 160014, India
SOURCE: Journal of Pharmaceutical Sciences (2005) 94(3),
676-687
CODEN: JPMSAE; ISSN: 0022-3549
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Inclusion complexation between **celecoxib**, a specific
cyclooxygenase II inhibitor, and beta-cyclodextrin (β -CD) was studied
in solution and solid state. Drug cyclodextrin complexes were prepared by
spray drying while phys. mixts. were obtained by simple blending.
Inclusion complexes were characterized by NMR spectroscopy (NMR),
differential scanning calorimetry (DSC), X-ray diffractometry (XRD), SEM
(SEM), IR spectroscopy (IR), and polarimetry. Phase solubility anal. was
carried out to determine the stability constant Solubility studies revealed
the
existence of a 1:1 complex between **celecoxib** and β -CD. NMR
studies suggested a strong interaction between **celecoxib** and
 β -CD prepared by spray drying. XRD and SEM anal. illustrated that
celecoxib existed as an **amorphous** complexed form in
spray-dried complexes. Dissoln. studies showed that the **celecoxib**
entrapped in spray-dried complexes dissolved much faster than the
uncomplexed drug and phys. mixts. The data obtained suggest that
celecoxib forms an inclusion complex with β -CD in solution and
solid state, which was confirmed by various anal. techniques. A shorter
t50% of dissoln. is found for the formulation prepared by spray drying when
compared on a weight basis in a USP II apparatus
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:861964 CAPLUS
DOCUMENT NUMBER: 142:183060
TITLE: Stability and Solubility of **Celecoxib**-PVP
Amorphous Dispersions: A Molecular Perspective
AUTHOR(S): Gupta, Piyush; Kakumanu, Vasu Kumar; Bansal, Arvind K.
CORPORATE SOURCE: Department of Pharmaceutical Technology
(Formulations), National Institute of Pharmaceutical
Education and Research, Punjab, 160 062, India
SOURCE: Pharmaceutical Research (2004) 21(10), 1762-1769
CODEN: PHREEB; ISSN: 0754-8741
PUBLISHER: Springer Science+Business Media, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The purpose of the current study is to evaluate the solubility advantage
offered by **celecoxib** (CEL) **amorphous** systems and to
characterize and correlate the phys. and thermodyn. properties of CEL and
its **amorphous** mol. dispersions containing poly(vinylpyrrolidone)
(PVP). The measurement of crystalline content, glass transition temps., and
enthalpy relaxation was performed using differential scanning calorimetry.
Solubility and dissolns. studies were conducted at 37°C to elucidate
release mechanisms. Further, the **amorphous** systems were

characterized by polarized light microscopy and x-ray powder diffraction studies. The PVP content has a prominent effect on the stability and solubility profiles of **amorphous** systems. A dispersion of 20% weight/weight PVP with CEL resulted in a maxima in terms of solubility enhancement

and lowering of relaxation enthalpy. The release of drug from **amorphous** mol. dispersions was found to be drug-dependent and independent of the carrier. The solubility enhancement and enthalpy relaxation studies with respect to PVP concentration helped in a better prediction of role of carrier and optimization of concentration in the use of solid dispersions or **amorphous** systems. The drug release mechanism is drug-controlled rather than carrier-controlled.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:782310 CAPLUS

DOCUMENT NUMBER: 141:319758

TITLE: Physical Stability and Solubility Advantage from

Amorphous Celecoxib: The Role of

Thermodynamic Quantities and Molecular Mobility

AUTHOR(S): Gupta, Piyush; Chawla, Garima; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology
(Formulations), National Institute of Pharmaceutical
Education and Research, Punjab, 160062, India

SOURCE: Molecular Pharmaceutics (2004), 1(6), 406-413

CODEN: MPOHBP; ISSN: 1543-8384

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Glassy pharmaceuticals, characterized by excess thermodyn. properties, are theor. more soluble than their crystalline counterparts. The practical solubility

advantage of the **amorphous** form of **celecoxib** (CEL) is lost due to its proclivity to lose energy and undergo solvent-mediated devitrification. Theor. assessment of solubility advantage using differences in isobaric heat capacities (C_p) revealed a 7-21-fold enhancement in the solubility of the **amorphous** form over that of the crystalline state of CEL. The present study attempts to unveil these differences between exptl. and theor. solubility using thermodyn. parameters such as free energy, enthalpy, and entropy. **Amorphous** CEL exhibited 1.3-1.5 times enhancement in C_p over that for the crystalline form. The zero and critical

mol.

mobility regions, represented by Kauzmann temperature (T_K) and glass transition temperature (T_g), were found to lie near 246 and 323 K, resp., for **amorphous** CEL. The fictive temperature (T_f), an indicator of the configurational entropy of glass, was determined for glassy CEL, signifying the retention of considerable mol. mobility in the glassy phase that may favor nucleation even below T_g . Further, the estimation of various thermodyn. quantities and strength/fragility parameters ($D = 11.5$ and $m = 67.0$) postulated the classification of glassy CEL into moderately fragile liquid, as per Angell's classification. A comprehensive understanding of such thermodyn. facets of **amorphous** form would help in rationalizing the approaches toward development of stable glassy pharmaceuticals with adequate solubility advantage.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:698147 CAPLUS
 DOCUMENT NUMBER: 141:212774
 TITLE: Lipophilic compositions containing therapeutic agents with low water solubility
 INVENTOR(S): Leigh, Mathew Louis Steven; Van Hoogevest, Peter; Quinton, Jacques; Leigh, Steve
 PATENT ASSIGNEE(S): Phares Pharmaceutical Research N.V., Neth. Antilles
 SOURCE: PCT Int. Appl., 13 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071494	A2	20040826	WO 2004-EP1355	20040213
WO 2004071494	A3	20041216		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-250900 A 20030213

AB There is described dry compns. comprising lipophilic compds. associated with low viscosity grades of water-insol. polymer and optionally hydrophilic agents associated either as monomol. or **amorphous** complexes. There is also described a method of preparing said lipophilic polymer complexes from a solution or homogeneous dispersion employing either water miscible or immiscible organic solvents. The lipophilic polymer complex is precipitated from the solution comprising a water miscible solvent by dilution with water, separating out the precipitated complex, washing, drying and conversion to oral and topical dosage forms. The lipophilic polymer complex may also be prepared by solvent removal involving spray drying or vacuum drying under elevated temps. using either water miscible or water immiscible solvents. The compns. are characterized by improved dissoln. and solubility of the associated compound in aqueous medium. For example, nifedipine 100 and Et cellulose 100 mg were dissolved in 10 mL NMP. The clear solution was added to a ten-fold excess of water. The resulting precipitate was collected and washed with water. The wet mass was dried for 8 h at 30° in a vacuum oven. The resulting free-flowing fine powder was used to fill gelatin capsules for oral administration.

L2 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:120620 CAPLUS
 DOCUMENT NUMBER: 140:169621
 TITLE: Stable **amorphous celecoxib**

INVENTOR(S): composite and process therefor
Zhuang, Hong; Gao, Ping
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004030151	A1	20040212	US 2003-431853	20030508
US 6864373	B2	20050308		
WO 2004041243	A2	20040521	WO 2003-US14563	20030508
WO 2004041243	A3	20041007		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1505987	A2	20050216	EP 2003-799770	20030508
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

PRIORITY APPLN. INFO.: US 2002-379968P P 20020513
WO 2003-US14563 W 20030508

AB A process is provided for preparing a **celecoxib**-crystallization inhibitor composite wherein at least a detectable amount of **celecoxib** is in **amorphous** form. Also provided are compns. prepared according to such a process. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount. A mixture containing **celecoxib** 500 µg/mL, ethanol 1%, HPMC 2.5%, and water q.s. 100% was prepared and stirred at room temperature for 21 days, the precipitate was then removed from the mixture by filtration and washed with water. The precipitate was then analyzed using X-Ray diffraction to show there was no evidence of any crystalline material. The data suggested that **celecoxib** in precipitate separated from the mixture was **amorphous**.

L2 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:848649 CAPLUS

DOCUMENT NUMBER: 140:362805

TITLE: Characterization of solid-state forms of **celecoxib**

AUTHOR(S): Chawla, Garima; Gupta, Piyush; Thilagavathi, R.; Chakraborti, Asit K.; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research, Nagar, 160 062, India

SOURCE: European Journal of Pharmaceutical Sciences (2003), 20(3), 305-317

CODEN: EPSCED; ISSN: 0928-0987

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This study deals with the generation and characterization of various solid-state forms of **celecoxib**, a selective cyclooxygenase-2 (COX-2) inhibitor. The drug was subjected to polymorphic screen using different solvents to explore the possibility of existence of different solid forms. N,N-Di-Me acetamide (DMA) and N,N-DMF (DMF) yielded solvates in 1:1 stoichiometric ratio. Quench cooling of the melt resulted in **amorphous** form of the drug. All these solid-state forms were characterized by thermoanal. (DSC, TGA, HSM), crystallog. (XRD), microscopic (polarized, SEM), spectroscopic (FTIR), and elemental anal. techniques. Solubility and van't Hoff studies were carried out for their thermodyn. interpretation. Influence of morphol. of different solid-state forms on flow behavior was also investigated. Mol. modeling studies were used to elucidate the interaction between solute and solvent mols. in the solvate.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:837584 CAPLUS

DOCUMENT NUMBER: 139:328445

TITLE: Process for obtaining **amorphous** solid pharmaceutical particles

INVENTOR(S): Perrut, Michel; Jung, Jennifer; Leboeuf, Fabrice

PATENT ASSIGNEE(S): Separex, Fr.

SOURCE: Fr. Demande, 30 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2838654	A1	20031024	FR 2002-5046	20020423
FR 2838654	B1	20041105		
WO 2003090668	A2	20031106	WO 2003-FR1255	20030418
WO 2003090668	A3	20040415		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: FR 2002-5046 A 20020423

AB The present invention relates to a process of obtaining **amorphous** solid pharmaceutical particles with a controlled particle size. This process comprises dissolving the product within a compressed fluid, followed by atomization by an inert gas, and maintaining the atomization chamber at a temperature much lower than the temperature of vitreous transition of the product, preferentially at least 30° below this temperature to produce

the desired particles. By using compressed CO₂, particles of desired particle size of **celecoxib** can be obtained.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:940035 CAPLUS

DOCUMENT NUMBER: 139:169110

TITLE: Enthalpy Relaxation Studies of **Celecoxib Amorphous** Mixtures

AUTHOR(S): Kakumanu, Vasu Kumar; Bansal, Arvind K.

CORPORATE SOURCE: Department of Pharmaceutical Technology, National Institute of Pharmaceutical Education and Research, Punjab, 160 062, India

SOURCE: Pharmaceutical Research (2002) 19(12), 1873-1878

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Kluwer Academic/Plenum Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of this study was to compare the structural relaxation and mol. mobility of **amorphous celecoxib** (CEL) with that of CEL **amorphous** mixts. consisting of various excipients and to study the effect of different excipients on the relaxation of high-energy **amorphous** systems. The measurement of glass transition temps. (T_g) and enthalpy relaxation were performed using differential scanning calorimetry. The interactions between drug and excipients and the absence of crystalline forms were further confirmed by conducting Fourier transform IR spectroscopic and x-ray powder diffraction studies on same samples. All samples exhibited a single T_g value. Polymers had a prominent effect on the lowering of the relaxation rate in **amorphous** CEL. The lowering of the rate of relaxation was directly dependent on the concentration and type of polymer used. The total enthalpy required for relaxation was same, although additives affected the rate of relaxation. In absence of any specific interactions during Fourier transform IR studies, it was concluded that the anti-plasticizing activity of polymers is responsible for the stabilization of CEL **amorphous** systems. Glassy **amorphous** dispersions of CEL exhibited a complex type of relaxation pattern, which failed to fit in Kohlrausch-Williams-Watts equation with respect to calcn. of relaxation time consts.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:754995 CAPLUS

DOCUMENT NUMBER: 137:268473

TITLE: Porous drug matrices and methods of manufacture thereof

INVENTOR(S): Straub, Julie; Altreuter, David; Bernstein, Howard; Chickering, Donald E.; Khattak, Sarwat; Randall, Greg

PATENT ASSIGNEE(S): Acusphere Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U. S. 6,395,300.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

-----	-----	-----	-----	-----
US 2002142050	A1	<u>20021003</u>	US 2002-53929	20020122
US 6395300	B1	20020528	US 1999-433486	19991104
US 6645528	B1	20031111	US 2000-694407	20001023
ZA 2001010347	A	20030730	ZA 2001-10347	20011218
US 2005048116	A1	20050303	US 2004-924642	20040824
US 2005058710	A1	20050317	US 2004-928886	20040827
PRIORITY APPLN. INFO.:			US 1999-136323P	P 19990527
			US 1999-158659P	P 19991008
			US 1999-433486	A2 19991104
			US 2002-53929	A3 20020122

AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form,

preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in

a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in **amorphous** form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Thus, 5.46 g of PEG 8000, 0.545 g of prednisone, and 0.055 g of Span 40 were dissolved in 182 mL of methylene chloride. A solution of 3.27 g of ammonium bicarbonate in 18.2 mL of water was added to the organic solution (phase ratio 1:10) and homogenized for 5 min at 16,000 RPM. The resulting emulsion was spray dried on a benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas.

L2 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:676581 CAPLUS

DOCUMENT NUMBER: 135:216023

TITLE: Micronized pharmaceutical sulfonamides or sulfones

INVENTOR(S): Reverchon, Ernesto

PATENT ASSIGNEE(S): Eco2 S.A., Switz.

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2001066090	A1	<u>20010913</u>	WO 2001-CH131	20010301
W: AU, CA, CN, IL, JP, <u>NZ</u> , <u>SG</u> , US, ZA				

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, TR

EP 1263412 A1 20021211 EP 2001-905573 20010301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY, TR

PRIORITY APPLN. INFO.:

CH 2000-422 A 20000304
WO 2001-CH131 W 20010301

AB By means of the action of a supercrit. fluid (SCF), for example supercrit. carbon dioxide (SCCO₂), substances of pharmaceutical use are precipitated in form

of **amorphous** or semicryst. particles of micrometric or submicrometric dimensions. Said substances would most typically be sulfonamides or sulfones such as Nimesulide, dissolved in an organic solvent such as 1-methyl-2-pyrrolidone (NMP) or dimethylsulfoxide (DMSO). The process parameters are such as to maximize the solubility of the organic solvent

in the SCF and minimize the solubility of the substance to be micronized in the SCF. The **amorphous** or semicryst. state of the particles so obtained, allow one to enhance the pharmacokinetics of the substance. For example, by means of the supercrit. antisolvent technique **amorphous** or semicryst. Nimesulide particles were produced. The substance was dissolved preferably in 1-methyl-2-pyrrolidone (NMP). The resulting solution should possess a concentration of 0.1-100 mg/mL, preferably

10 mg/mL. The solution was fed into the chamber at a flow rate of 0.1-10 mL/min, preferably at 1 mL/min, at a d. of 1100 kg/m³, in quantities ranging from 20 to 50 mL, preferably 30 mL. The antisolvent, preferably carbon dioxide, is fed into the chamber at a flow rate of 1000-10,000 mL (gas STP)/min, preferably at 8000 mL (gas STP)/min, at a pressure of 78-400 bar, preferably 85 bar, and at a temperature of 30-60°, preferably 40°. The resulting ratio between flow rate of solvent and flow rate of antisolvent is 1.25 E-04. The product was finally washed by passing only antisolvent through the chamber for a period of time ranging from 60 to 100 min, preferably 80 min. The yield of recovered Nimesulide (300 mg) was > 95%.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:435052 CAPLUS

DOCUMENT NUMBER: 135:37203

TITLE: Solid-state form of **celecoxib** having enhanced bioavailability

INVENTOR(S): Hageman, Michael J.; He, Xiaorong; Kararli, Tugrul T.; Mackin, Lesley A.; Miyake, Patricia J.; Rohrs, Brian R.; Stefanski, Kevin J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042221	A1	20010614	WO 2000-US32435	20001206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
NZ 514059 A 20040227 NZ 2000-514059 20001201
US 2004087640 A1 20040506 US 2000-728040 20001201
AU 2001019311 A5 20010618 AU 2001-19311 20001206
EP 1150959 A1 20011107 EP 2000-982255 20001206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
US 2002006951 A1 20020117 US 2000-730663 20001206
BR 2000008058 A 20020326 BR 2000-8058 20001206
JP 2004500358 T2 20040108 JP 2001-543522 20001206
NZ 513964 A 20040130 NZ 2000-513964 20001206
NZ 513960 A 20040227 NZ 2000-513960 20001206
NO 2001003855 A 20011005 NO 2001-3855 20010808
ZA 2001007146 A 20020829 ZA 2001-7146 20010829
ZA 2001007148 A 20021129 ZA 2001-7148 20010829
ZA 2001007149 A 20030228 ZA 2001-7149 20010829
ZA 2002007445 A 20031013 ZA 2002-7445 20020917
PRIORITY APPLN. INFO.: US 1999-169856P P 19991209
US 2000-730663 A 20001206
WO 2000-US32435 W 20001206

AB The selective cyclooxygenase-2 inhibitory drug **celecoxib** is provided in **amorphous** form. Also provided is a **celecoxib**-crystallization inhibitor composite comprising particles of **amorphous celecoxib** or a **celecoxib** drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a **celecoxib**-crystallization inhibitor composite and one or more excipients. **Celecoxib** drug substance and polymer composites with HPMC and PVP were prepared by spray drying. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:434782 CAPLUS

DOCUMENT NUMBER: 135:37187

TITLE: Solid-state form of **celecoxib** having enhanced bioavailability

INVENTOR(S): Hageman, Michael J.; He, Xiaorong; Kararli, Tugrul T.; Mackin, Lesley A.; Miyake, Patricia J.; Rohrs, Brian R.; Stefanski, Kevin J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041536	A2	20010614	WO 2000-US30180	20001204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
NZ 514059	A	20040227	NZ 2000-514059	20001201
US 2004087640	A1	20040506	US 2000-728040	20001201
AU 2001020412	A5	20010618	AU 2001-20412	20001204
US 2002006951	A1	20020117	US 2000-730663	20001206
NZ 513964	A	20040130	NZ 2000-513964	20001206
NZ 513960	A	20040227	NZ 2000-513960	20001206
ZA 2001007146	A	20020829	ZA 2001-7146	20010829
ZA 2001007148	A	20021129	ZA 2001-7148	20010829
ZA 2001007149	A	20030228	ZA 2001-7149	20010829
ZA 2002007445	A	20031013	ZA 2002-7445	20020917
PRIORITY APPLN. INFO.:			US 1999-169856P	P 19991209
			WO 2000-US30180	W 20001204

AB The selective cyclooxygenase-2 inhibitory drug **celecoxib** is provided in **amorphous** form. Also provided is a **celecoxib** drug substance wherein the **celecoxib** is present, in at least a detectable amount, as **amorphous celecoxib**. Also provided is a **celecoxib**-crystallization inhibitor composite comprising particles of **amorphous celecoxib** or a **celecoxib** drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a **celecoxib**-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing **amorphous celecoxib**, a **celecoxib** drug substance of the invention, a **celecoxib**-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

69.24

69.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-15.33

-15.33

STN INTERNATIONAL LOGOFF AT 16:36:49 ON 31 MAR 2005